• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br E Padfield H P Ellis K M Kurian Current


    [31] E. Padfield, H.P. Ellis, K.M. Kurian, Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma, Frontiers in oncology 5 (2015) 5.
    S. Dangelmajer, H. Guerrero-Cazares, A. Quinones-Hinojosa, PAR1 inhibition sup-presses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo, Oncogene 35 (29) (2016) 3817.
    D. Davis, A. Benraiss, K. Walter, P. Achanta, Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes, Cell Rep. 3 (6) (2013) 2127–2141.
    [37] K.L. Chaichana, H. Guerrero-Cazares, V. Capilla-Gonzalez, G. Zamora-Berridi,
    P. Achanta, O. Gonzalez-Perez, G.I. Jallo, J.M. Garcia-Verdugo, A. Quiñones-Hinojosa, Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells, J. Neurosci. Methods 180 (1) (2009) 116–125. [38] H. Guerrero-Cázares, K.L. Chaichana, A. Quiñones-Hinojosa, Neurosphere Culture and Human Organotypic Model to Evaluate Brain Tumor Stem Cells, Cancer Stem Cells, Springer, 2009, pp. 73–83.
    [39] J. Kim, J.C. Sunshine, J.J. Green, Differential polymer structure tunes mechanism of cellular uptake and transfection routes of poly(beta-amino ester) polyplexes in human breast cancer cells, Bioconjug. Chem. 25 (1) (2014) 43–51.
    N. Mihelson, C.G. Eberhart, J. Laterra, J.J. Green, Bioreducible polymeric nano-particles containing multiplexed cancer stem cell regulating miRNAs inhibit glio-blastoma growth and prolong survival, Nano Lett. 18 (7) (2018) 4086–4094. [43] O.W. Griffith, Biologic and pharmacologic regulation of mammalian glutathione synthesis, Free Radic. Biol. Med. 27 (9) (1999) 922–935. [44] S.Y. Tzeng, L.J. Higgins, M.G. Pomper, J.J. Green, Biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s,
    J.J. Green, Biodegradable polymeric nanoparticles show high efficacy and specifi-city at DNA delivery to human glioblastoma in vitro and in vivo, ACS Nano 8 (5) (2014) 5141–5153.
    A. Levchenko, T. Lei, A. Quinones-Hinojosa, Human cerebrospinal fluid regulates proliferation and migration of stem cells through insulin-like growth factor-1, Stem Cell. Dev. 24 (2) (2014) 160–171.
    H. Guerrero-Cazares, A. Quinones-Hinojosa, S.M. Bezrukov, J. Zimmerberg, Shear forces during blast, not abrupt changes in pressure alone, generate calcium activity in human 958002-33-0 cells, PLoS One 7 (6) (2012) e39421. [51] S.Y. Tzeng, H. Guerrero-Cazares, E.E. Martinez, J.C. Sunshine, A. Quinones-Hinojosa, J.J. Green, Non-viral gene delivery nanoparticles based on poly(beta-amino esters) for treatment of glioblastoma, Biomaterials 32 (23) (2011) 5402–5410.
    Contents lists available at ScienceDirect
    Preventive Medicine
    journal homepage:
    Cancers attributable to infections in Canada T
    Karena D. Voleskya,b, , Mariam El-Zeina, Eduardo L. Francoa,b, Darren R. Brennerc, Christine M. Friedenreichd, Yibing Ruand, on behalf of the ComPARe Study Team1 a Gerald Bronfman Department of Oncology, Division of Cancer Epidemiology, McGill University, Montréal, Québec, Canada b Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada c Departments of Oncology and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada d Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada
    Population attributable risk
    Papillomavirus infections
    Helicobacter pylori
    Hepatitis viruses
    Infections are estimated to cause approximately 15% of the world's cancers with large geographic variations. Yet, Canadian estimates for specific cancer-causing infections are not available. To estimate the number of infection-associated cancers diagnosed among Canadian adults in 2015, we calculated population attributable risks (PARs) and the number of attributable cases for seven carcinogenic infections and their 20 associated cancers. A sys-tematic literature search was performed for each infection to obtain data on infection prevalence in the popu-lation and the relative risk or odds ratio associated with the cancer it causes. When mechanistic evidence suggested that detection of a given infection within cancer tissue was sufficient to attribute the cancer to the infection, prevalence among cancer cases was used to approximate the PAR. Data from 61 studies formed the basis of our analyses. The estimated number of infection-attributable cancer cases for 2015 was: 3828 for human papillomavirus (HPV), 2052 for Helicobacter pylori, 578 for Epstein-Barr virus, 509 for hepatitis B and C viruses (HBV, HCV), 100 for human herpesvirus type 8, and 30 cases for human T-cell lymphotropic virus type 1. These seven infections were responsible for 3.7% of cancers diagnosed among Canadian adults in 2015; 3.5% among men and 4.0% among women. The infections with the highest number of attributable cases are largely pre-ventable or treatable through vaccination (HBV and HPV), antibiotic therapy (H. pylori), or a combination of interventions (HCV), thereby representing an important target for reducing the infection-caused cancer burden among Canadians.